论文部分内容阅读
目的评价阿替普酶治疗急性脑梗死的临床疗效及其安全性。方法选取76例急性脑梗死患者,随机均分为试验组和对照组(n=38)。对照组患者均给予抗血小板聚集抑制剂、自由基清除剂,同时口服肠溶阿司匹林,伴脑水肿患者加用甘油果糖静滴及20%甘露醇;试验组在对照组治疗的基础上采用阿替普酶溶栓治疗。比较2组患者治疗前、治疗后6 h、24 h、7 d进行神经功能缺损评分。结果试验组与对照组的疗效比较差异有统计学意义(P<0.05);试验组经治疗后其神经功能缺损评分明显优于对照组评分,差异有统计学意义(P<0.05)。治疗组患者不良反应轻微,患者可以耐受。结论阿替普酶治疗急性脑梗死是安全有效的,并能明显改善患者的神经功能缺损症状。
Objective To evaluate the clinical efficacy and safety of alteplase in the treatment of acute cerebral infarction. Methods Totally 76 patients with acute cerebral infarction were randomly divided into experimental group and control group (n = 38). Control group patients were given anti-platelet aggregation inhibitor, free radical scavenger, while oral enteric-coated aspirin, with cerebral edema plus glycerol fructose intravenous infusion and 20% mannitol; the experimental group in the control group on the basis of treatment with Ati Enzyme thrombolytic therapy. The neurological deficit scores of two groups were compared before treatment, 6 h, 24 h, 7 d after treatment. Results There was significant difference in curative effect between experimental group and control group (P <0.05). After treatment, the neurological deficit score of the experimental group was significantly better than that of the control group (P <0.05). Adverse reactions in treatment group patients mild, patients can tolerate. Conclusion Alteplase is safe and effective in the treatment of acute cerebral infarction and can significantly improve the symptoms of neurological deficits in patients.